H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias  by Krivtsov, Andrei V. et al.
Cancer Cell
ArticleH3K79 Methylation Profiles Define
Murine and Human MLL-AF4 Leukemias
Andrei V. Krivtsov,1,5 Zhaohui Feng,1,5 Madeleine E. Lemieux,2 Joerg Faber,1 Sridhar Vempati,1,2 Amit U. Sinha,1,2
Xiaobo Xia,2 Jonathan Jesneck,2 Adrian P. Bracken,4 Lewis B. Silverman,1,2 Jeffery L. Kutok,3 Andrew L. Kung,1,2
and Scott A. Armstrong1,2,*
1Division of Hematology/Oncology, Children’s Hospital Boston
2Department of Pediatric Oncology, Dana-Farber Cancer Institute
3Department of Pathology, Brigham and Women’s Hospital
Harvard Medical School, Boston, MA 02115, USA
4Department of Genetics, The Smurfit Institute, Trinity College, Dublin 2, Ireland
5These authors contributed equally to this work
*Correspondence: scott.armstrong@childrens.harvard.edu
DOI 10.1016/j.ccr.2008.10.001
SUMMARY
We created amousemodel wherein conditional expression of anMll-AF4 fusion oncogene induces B precur-
sor acute lymphoblastic (ALL) or acute myeloid leukemias (AML). Gene expression profile analysis of the ALL
cells demonstrated significant overlap with human MLL-rearranged ALL. ChIP-chip analysis demonstrated
histone H3 lysine 79 (H3K79) methylation profiles that correlated with Mll-AF4-associated gene expression
profiles inmurine ALLs and in humanMLL-rearranged leukemias. HumanMLL-rearranged ALLs could be dis-
tinguished from other ALLs by their H3K79 profiles, and suppression of the H3K79 methyltransferase DOT1L
inhibited expression of critical MLL-AF4 target genes. We thus demonstrate that ectopic H3K79 methylation
is a distinguishing feature ofmurine and humanMLL-AF4 ALLs and is important formaintenance ofMLL-AF4-
driven gene expression.INTRODUCTION
Leukemias mediated by MLL rearrangements possess unique
clinical and biological features. MLL rearrangements can be
found in acute lymphoblastic leukemia (ALL), acute myeloid leu-
kemias (AML), and acute biphenotypic or mixed-lineage leuke-
mia (MLL). MLL translocations are present in over 70% of cases
of infant leukemias (Biondi et al., 2000) and in general account for
approximately 5% of ALLs, 5%–10% of AMLs, and a significant
portion of acute biphenotypic or mixed-lineage leukemias (Huret
etal., 2001). Patients withMLL-rearranged ALLhave aparticularly
unfavorable prognosis as compared to patients with other forms
of ALL (Chen et al., 1993). To date, more than 50 MLL fusion part-
ner genes have been reported (Ayton and Cleary, 2001; Krivtsov
and Armstrong, 2007). The t(4;11)(q21;q23) encodes MLL-AF4
and is the most frequent MLL translocation found in ALL.CMultiple mouse models have been developed that recapitulate
MLL-rearranged AML (reviewed in Ayton and Cleary, 2001).
However, development of models that faithfully recapitulate
MLL fusion-mediated ALL has proven more difficult. Constitutive
Mll-AF4 knockin results in mixed lymphoid/myeloid hyperplasia
and mature B cell neoplasms in mice (Chen et al., 2006). Condi-
tional expression ofMll-AF4 based on interchromosomal recom-
bination in lymphoid lineages produces mature B cell lympho-
mas (Metzler et al., 2006). Thus, further development of murine
models of MLL-rearranged ALL is needed.
MLL is a mammalian homolog ofDrosophila trithorax and pos-
sesses multiple functional domains, including amino-terminal AT
hooks that bind DNA and a carboxy-terminal Su(var)3-9,
Enhancer-of-zeste, Trithorax (SET) domain that methylates
lysine 4 of histone H3 (H3K4). H3K4 methylation is associated
with transcriptional activation (reviewed in Shilatifard, 2006),SIGNIFICANCE
The t(4;11) encodes anMLL-AF4 fusion protein and predicts a particularly poor prognosis when found in acute lymphoblas-
tic leukemia (ALL). Recent studies suggest certain MLL fusion proteins enhance gene expression by recruitment of the his-
tone H3 lysine79 (H3K79) methyltransferase DOT1L. We demonstrate that H3K79 methylation is enhanced at many loci in
leukemia cells from a murine model of Mll-AF4 and in human MLL-AF4 leukemia cells, and that this elevation is correlated
with enhanced gene expression. Furthermore, suppression of H3K79 methylation leads to inhibition of gene expression in
MLL-AF4 cells. These data demonstrate that inhibition of DOT1Lmay be a therapeutic approach in this disease and that this
mouse model should be useful for assessment of therapeutic approaches for MLL-rearranged ALL.ancer Cell 14, 355–368, November 4, 2008 ª2008 Elsevier Inc. 355
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H3K79 Methylation in MLL-Rearranged ALLand MLL positively regulates expression of clustered homeobox
(HOX) and other genes during development, at least in part via
H3K4 methylation (Milne et al., 2002; Nakamura et al., 2002).
Mll has important roles in development, including hematopoietic
development (Hess et al., 1997; Jude et al., 2007).
MLL translocations invariably encode fusion proteins that
have lost the H3K4 methyltransferase (SET) domain. However,
MLL fusion proteins retain the ability to bind HOX genes and
other promoter regions and are associated with enhanced
gene expression (Armstrong et al., 2002; Guenther et al., 2005;
Rozovskaia et al., 2001; Yeoh et al., 2002; Zeisig et al., 2004).
Several mechanisms have been proposed as to how MLL fu-
sions may deregulate gene expression, including recruitment
of abnormal histone modification activities (Cheung et al.,
2007; Krivtsov and Armstrong, 2007; Okada et al., 2005). For ex-
ample, MLL-AF10 and MLL-ENL have been shown to recruit the
non-SET domain methyltransferase DOT1L, which promotes
methylation of histone H3 lysine 79 (H3K79) on the HOXA9 pro-
moter (Mueller et al., 2007; Okada et al., 2005; Zeisig et al., 2005).
Since H3K79 methylation is linked to positive transcriptional
regulation (Schubeler et al., 2004; Shilatifard, 2006), DOT1L-
mediated methylation of H3K79 may contribute to increased
expression of HOXA9 in MLL-AF10- and MLL-ENL-induced leu-
kemias. Furthermore, AF10, ENL, and other MLL fusion partners
such as AF4 and AF9 are normally found in nuclear complexes
associated with DOT1L (Bitoun et al., 2007; Mueller et al.,
2007; Okada et al., 2005; Zeisig et al., 2005; Zhang et al.,
2006). Thus, aberrant recruitment of DOT1L to the promoters
of MLL target genes may be a common feature of many onco-
genic MLL fusion proteins. However, the extent of H3K79 meth-
ylation changes and the specificity of these epigenetic changes
for MLL-rearranged leukemias have not been defined.
Here, we report the development of a murine model in which
conditional expression of MLL-AF4 induces both ALL and
AML. Genome-wide assessment of gene expression and
H3K79 methylation demonstrates that this model faithfully reca-
pitulates human ALL resulting from MLL-AF4 translocation and
identifies ectopic H3K79 methylation as an important part of
MLL-AF4-driven gene expression and transformation.
RESULTS
Generation of a Conditional Mll-AF4 Knockin Mouse
We used a conditional expression approach that proved suc-
cessful for development of an Mll-Cbp myelodysplasia/AML
model to create a model in which the Mll-AF4 fusion product
was conditionally expressed from the endogenous Mll locus.
We engineered a conditional Mll-AF4stop targeting construct by
replacing the Cbp cDNA in the previously reported Mll-Cbpstop
targeting vector (Wang et al., 2005) with a cDNA encoding the
C-terminal portion of human AF4 (Figure 1A). This generated
a targeting construct that placed the human AF4 sequence in
the murine Mll exon 8, downstream of a transcriptional stop
site flanked by LoxP sites, which allows conditional expression
of an Mll-AF4 fusion RNA upon expression of Cre recombinase
(Figure 1B). The construct was electroporated into CJ7 mouse
embryonic stem cells (Swiatek and Gridley, 1993), and clones
possessing the targeted allele were selected by Southern blot
(Figure 1C) and used to achieve germline transmission of the356 Cancer Cell 14, 355–368, November 4, 2008 ª2008 Elsevier Incknockin allele. Mice heterozygous for the Mll-AF4stop conditional
allele were born at slightly less than Mendelian frequency, pre-
sumably due to heterozygosity for Mll (Yu et al., 1995). Founder
mice were backcrossed to C57BL6/129 F1 mice. We used Mll-
AF4-specific primers to confirm the absence of the fusion RNA
in bone marrow from mice heterozygous for theMll-AF4stop allele.
Mll-AF4 Expression Enhances Serial Replating
of Lymphoid Progenitors
First, we determined whether expression of Mll-AF4 could trans-
form lymphoid cells in vitro. We collected bone marrow from Mll-
AF4stop (MA4) heterozygous mice (three experiments, five mice
each) 5 days after 5-fluorouracil (5-FU) treatment and trans-
duced cells with retroviruses encoding either GFP control
(MIG) or Cre-GFP (Cre) to initiate expression of Mll-AF4. Cells
were then cultured in semisolid media supplemented with IL-7,
SCF, and FLT3. After 14 days of culture, over 90% of cells in
both Cre and MIG groups expressed CD19 and B220. Weekly re-
plating of 13 104 MIG-transduced cells exhausted their colony-
forming potential by the third week, while similar replating of
Cre-transduced cells did not exhaust their replating potential
for at least 6 weeks (see Figure S1A available online). To assess
for gene expression changes associated with Mll-AF4 expres-
sion, we extracted RNA from 13 105 cells at the end of the sec-
ond week of plating and amplified, labeled, and hybridized
labeled RNA to Affymetrix mouse 430 A2.0 microarrays. Super-
vised analysis identified HoxA5, HoxA9, Runx2, Meis1, and Mylk
among the 20 most upregulated genes in the cells expressing
Mll-AF4 (Figure S1B). These genes are also found as central
members of early gene expression changes associated with
MLL-AF9 expression in myeloid cells and in human
MLL-rearranged lymphoblastic leukemias (Armstrong et al.,
2002; Krivtsov et al., 2006). Thus, conditional expression of Mll-
AF4 in lymphoid cells leads to in vitro transformation and gene ex-
pression changes associated with human MLL fusion leukemias.
Mll-AF4 Expression Induces Acute Leukemias
The initial strategy we used to activate Mll-AF4 expression uti-
lized a self-excising retrovirus that transiently expresses Cre re-
combinase in transduced cells (Silver and Livingston, 2001). We
either collected bone marrow (BM) from heterozygous MA4 mice
5 days after 5-FU treatment or used 5-FU-untreated bone mar-
row depleted for cells expressing CD3, CD4, CD8a, F4/80,
B220, Gr1, and TER119 (Lin). BM cells were transduced with
retroviruses encoding either ‘‘hit-and-run Cre’’ (HR-Cre) or GFP
(MIG) and transplanted into lethally or sublethally irradiated syn-
geneic recipients. The expression of Mll-AF4 in HR-Cre cells but
not MIG-transduced cells was confirmed by RT-PCR (Figure 1D).
Mice (n = 43) expressing theMll-AF4 allele as a result of retroviral
transduction of Cre developed a fatal disease (Table 1; Figures
S2A and S2B) consistent with acute leukemia including bone
marrow replacement, splenomegaly, and variable lymphade-
nopathy (Table 1; Figure 2A). Mice transplanted with BM from
MA4 mice (n = 20) transduced with MIG did not develop leukemia
(Figure S2A).
In order to confirm leukemia development in a purely genetic
model, we crossed MA4 mice with mice transgenic for Mx1-Cre
(Kuhnetal., 1995).Mx1-Cre3MA4 mice and control littermates re-
ceived three intraperitoneal injections of polyinosinic/polycytidylic.
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H3K79 Methylation in MLL-Rearranged ALLacid (pIpC). Mll-AF4 transcript expression was confirmed by
RT-PCR. Fourteen of 22 Mx1-Cre 3 MA4 mice developed a
disease consistent with acute leukemia, and three died from un-
known causes within 250 days from the initial pIpC treatment.
Mice that possessed onlyMx1-CreorMll-AF4stop did not develop
leukemia (Table 1; Figure S2C). The median latency of leukemias
Table 1. Characteristics of Mice with Mll-AF4-Induced Leukemias
Latency in Days
(Mean Range)
SP Weight in mg
(Mean Range)
WBC 3 1000/ml
(Mean Range)
HCT %
(Mean Range)
Platelets 3 1000/ml
(Mean Range)
% of Leukemia
Cells in BM
Normal 70–110 5–10 45–47 800–1400
tBM TR (n = 37)
ALL (n = 11) 122.8 (71–220) 425.5 (200–670) 138.0 (17–476) 32.1 (20–40.9) 447.9 (144–920) 85.3 (52–99)
AML (n = 23) 75.6 (25–221) 404.8 (150–800) 124.8 (8–389) 24.7 (8.9–41) 310.3 (70–824) 86.0 (54–98)
MLL (n = 3) 92 (81–105) 666.7 (390–810) 224.3 (155–281) 23.7 (17.7–26) 201 (99–312) 59 (39–75)
Lin TR (n = 7)
ALL (n = 4) 67.5 (62–75) 287.5 (200–450) 459.8 (236–748) 25.5 (16.1–39) 373.5 (251–496) 88.3 (67–98)
AML (n = 2) 103 (98–108) 515 (470–560) 72.5 (23–122) 33.6 (29.9–37) 394.5 (367–422) 83.5 (80–87)
Alive (n = 1)
Mx1-Cre (n = 22)
ALL (n = 8) 152.3 (120–242) 691 (260–2100) 43.0 (5–92.6) 30.3 (5.2–44) 640 (102–1683) 46.6 (24–86)
AML (n = 6) 143.5 (67–240) 485.0 (300–910) 84.3 (6–279) 23.5 (10.4–40) 732 (400–1463) 92.2 (84–98)
No leukemia (n = 3)
Alive (n = 5)
SP, spleen; WBC, white blood cells; HCT, hematocrit; BM, bone marrow; TR, transgenic.
Figure 1. Generation of Mice with a Conditional Mll-AF4stop Allele
(A) Schematic representation of the MLL-AF4 fusion protein including a number of protein motifs. AT-h 1–3, AT hooks; SNL1 and SNL2, speckled nuclear local-
ization sites; RD1 and RD2, transcriptional repression domain consisting of two functional subunits; ALF, homologous regions among the AF4/FMR2 family mem-
bers; Ser, serine-rich regions that contain a transactivation domain; NL, nuclear localization signal; CHD, C-terminal homology domain conserved between the
FMR2, AF4, and LAF4 family of transcription factors.
(B) A diagrammatic description of the Mll-AF4stop knockin allele. Mll exons are numbered 4 to 9. The polyadenylation (pA) site and puromycin (puro) resistance
cassette are shown. EcoRI (RI) and BamHI (BI) sites and Mll forward (F) and AF4 reverse (R) primers used for Mll-AF4 fusion RNA detection are shown.
(C) Southern blot analysis of EcoRI-digested genomic DNA from wild-type and targeted embryonic stem cells (ESC) probed with the 50 probe shown in (B).
(D) RT-PCR analysis ofMll-AF4 transcript expression in total bone marrow from Mll-AF4stop mice retrovirally transduced with either ‘‘hit-and-run’’ Cre (HR-Cre) or
MSCV-MIG (control). M, molecular weight marker in base pairs (bp).Cancer Cell 14, 355–368, November 4, 2008 ª2008 Elsevier Inc. 357
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of the transplant models (82 and 71 days), and these mice tended
to have less BM involvement than mice that received the retrovir-
ally delivered Cre (Table 1; Figures S2A–S2C).
Histopathologic evaluation of tissues from moribund mice dem-
onstrated bone marrow, splenic, and liver infiltration with immature
hematopoietic cells (Figure 2A). The 31 cases with a morphologic
appearancemostconsistent withmyeloid leukemiapossessed im-
munophenotypes consistent with AML: Mac1+Gr1+B220CD19
(n = 26) (Figure S2D), Mac1Gr1+B220CD19 (n = 3), or
Mac1+Gr1B220CD19 (n = 2). The 26 cases whose morpho-
logic appearances were most consistent with a lymphoid leukemia
possessed immunophenotypes that included expression of
the lymphoid markers B220 and/or CD19. Sixteen of 26 lymphoid-
appearing leukemias were B220+CD19+Mac1 (Figure 2B).
Southern and PCR analyses of genomic DNA from spleen cells iso-
lated from leukemic mice demonstrated that all CD19+B220+ leu-
kemias analyzed possessed a clonal DJH rearrangement (Fig-
ure 2D; Figures S2E and S2F). This type of leukemia was
therefore consistent with typical B cell ALL. None of the AMLs
analyzed possessed DJH rearrangements (Figure 2D; Figures
S2E and S2F). Three lymphoid-appearing leukemias were
B220+CD19Mac1+ (Figure S2D), and based on the coexpression
of B220 and Mac1, these leukemias were termed mixed-
Figure 2. Characterization of Mll-AF4-Me-
diated B Precursor ALLs
(A) Histopathologic analysis of B precursor (B-pr)
ALL inMll-AF4mice. Cells consistent with lympho-
blasts are found in the peripheral blood (left). The
bone marrow (center) and spleen (right) are infil-
trated with leukemia cells.
(B) FACS analysis of normal bone marrow (BM)
(left) and leukemic BM (right) using antibodies
against B220, Gr1, Mac1, and CD19.
(C) Detailed immunophenotypic analysis of normal
BM (top), leukemic BM from a mouse with primary
ALL (1, middle), and ALL BM from a secondary re-
cipient mouse (2, bottom).
(D) PCR-based analysis showing germline or rear-
ranged immunoglobulin DJH heavy-chain loci in
AML cells (11), ALL cells (270, 15, and 17), NIH
3T3 cells, or normal splenocytes (WT SP). The ar-
row indicates germline (gl) DJH configuration. M,
molecular weight marker in kilobases (kb).
lineage leukemias (MLL). One of three pos-
sessed a single DJH configuration as
assessed by a PCR-based approach
(Figure S2E). Three leukemias were
B220+CD19Mac1, one of which pos-
sessed a clonal DJH rearrangement in sup-
port of a very early lymphoid arrest, and
thus were designated pro-B ALL (Figures
S2D and S2E). Four lymphoid-appearing
leukemias were CD19+B220Mac1. All
lymphoid leukemias expressed the Mll-
AF4 fusion RNA (Figure S2G).
We assessed the ability of the leukemias to initiate disease in
secondary recipient mice to functionally assess the presence of
leukemia-initiating cells (LICs). BM cells from mice with AML
(n = 1), MLL (n = 2), or B precursor (B-pr) ALL (n = 4) could ini-
tiate leukemia in secondary recipient mice (n = 21) when 33 104
cells were injected (data not shown). We performed limiting
dilution transplant experiments to determine the frequency of
LICs in the B220+CD19+ B-pr ALLs (n = 2) and found that all
mice (n = 22) that received as few as 1 3 103 sorted
B220+CD19+ leukemia cells developed an identical ALL (Fig-
ure 2C), whereas 3 of 9 mice that received 100 cells developed
leukemia. We also further characterized the MLLs (n = 2) for
LICs and found that all secondary recipient mice (n = 24) that re-
ceived 53 104 sorted B220+Mac1+ cells developed an identical
MLL (data not shown), whereas none of the mice (n = 20) that
received 1 3 103 cells developed leukemia. These data confirm
the development of an acute leukemia in this model system and
demonstrate the presence of LICs in leukemias with different
immunophenotypes.
We further characterized the CD19+B220+ leukemias and
defined the precise stage of B-lymphoid development that
most closely matched the leukemias. We performed immuno-
phenotypic analysis that assessed B220, CD43, IgM, and IgD ex-
pression to compare the ALL cells to various stages of B cell358 Cancer Cell 14, 355–368, November 4, 2008 ª2008 Elsevier Inc.
Cancer Cell
H3K79 Methylation in MLL-Rearranged ALLdevelopment. Bone marrow cells taken from wild-type mice
demonstrated appropriate percentages of B cells at various
stages of differentiation (Figure 2C). However, the majority of
lymphoid cells present in BM from mice with primary or second-
ary B-pr ALL were B220+CD43IgMIgD, most consistent with
mouse pre-B cells (Hardy, 1990). Thus, the leukemias represent
an expansion of cells that by immunophenotypic analysis are ar-
rested at the pre-B cell stage of development, thus confirming
their identity as B-pr ALL.
Murine Mll-AF4 ALL Recapitulates Human
MLL-Rearranged ALLs
To more definitively determine the developmental stage of
leukemia cells, we compared the global gene expression pattern
of the expanded leukemia cells to normal B cells. We isolated
RNA from 16 primary B-pr ALLs and normal lymphocyte popula-
tions (Hardy, 1990) including pro-B cells (LinB220+CD43+),
pre-B cells (LinB220+CD43IgMIgD), immature B cells
(LinB220+CD43IgM+IgD), and mature B cells
(LinB220+CD43IgM+IgD+) and amplified and hybridized RNA
to Affymetrix 430 A2.0 microarrays. Unsupervised hierarchical
clustering analysis demonstrated that 14 ALLs were more similar
to pre-B cells and that two ALLs were more similar to pro-B cells
than to immature B or mature B cells (Figure 3A), providing further
evidence for leukemia cell expansion at an early stage of B cell
development. The relationship between the ALL samples and
normal B cells was further tested by consensus clustering, which
demonstrated that ALLs 117 and 122 clustered separately and
that the other ALLs were most similar to pre-B cells (Figure S3A).
Supervised gene expression analysis demonstrated that mu-
rine B-pr ALL cells express high levels of certain HoxA cluster
genes but do not differentially express HoxB, HoxC, or HoxD
cluster genes (Figure 3B). The elevated expression of HoxA9
was confirmed by quantitative PCR (qPCR) (Figure S3B). The
murine ALL cells also expressed high levels of Meis1 as mea-
sured by microarrays and qPCR (Figure S3C), similar to human
MLL-rearranged ALL (Armstrong et al., 2002).
Next, to assess globally whether mouse Mll-AF4 ALLs recapit-
ulate gene expression profiles observed in human MLL-rear-
ranged ALLs, we compared gene expression signatures of
mouse Mll-AF4 ALL to humanMLL-rearranged ALL. We identified
the top 500 probe sets (386 genes) with increased expression in
murine Mll-AF4 B-pr ALL as compared to pre-B cells using a sig-
nal-to-noise statistic and converted them to human homologs
found on Affymetrix U133 arrays (259 genes). Gene set enrich-
ment analysis (GSEA) demonstrated strong enrichment (p <
0.014) of the murine Mll-AF4 signature in humanMLL-rearranged
ALLs as compared to MLL-germline ALLs (Ross et al., 2003;
Subramanian et al., 2005) (Figure 3C). These data demonstrate
that the ALLs in our mouse model recapitulate gene expression
programs found in human MLL-AF4-induced disease.
H3K79 Methylation in Murine Mll-AF4 ALL
Since AF4 associates with the DOT1L methyltransferase (Bitoun
et al., 2007), we hypothesized that Mll-AF4 may be associated
with ectopic H3K79 methylation. First, we determined that
Dot1L is ubiquitously expressed in B cell progenitors and B-pr
ALL (Figure S4A). We used chromatin immunoprecipitation
(ChIP) to assess histone methylation near the promoters ofCHoxA genes. We sorted pre-B cells and leukemia cells with a sim-
ilar immunophenotype and performed ChIP with antibodies di-
rected against dimethylated H3K79 (H3K79me2), trimethylated
lysine 27 (H3K27me3), trimethylated lysine 36 (H3K36me3), or
trimethylated lysine 4 (H3K4me3). We assessed the ChIP DNA
by qPCR using primers that spanned the promoter region of
HoxA9 and compared the amount of precipitated DNA as a per-
centage of input in normal versus leukemia cells (Figure S4B).
We found slightly elevated H3K4me3, no obvious change in
H3K27me3 or H3K36me3, and dramatically enhanced
H3K79me2 associated with HoxA gene promoters in the leuke-
mia cells (Figures 4A and 4C). Next, we assessed expression
levels of HoxA9 in pre-B ALLs and normal B cell progenitors
and found a strong correlation between the amount of
H3K79me2 and HoxA9 expression (Figure 4B). We expanded
our assessment and found enhanced H3K79me2 across much
of the HoxA cluster (Figure 4C). Given the data demonstrating
a potential role for DOT1L in some MLL-rearranged leukemias
and these data demonstrating enhanced H3K79me2 in Mll-AF4
ALL cells, we focused further assessment on H3K79 methylation.
Genome-wide assessment of DNA binding of MLL through the
use of ChIP followed by microarray analysis (ChIP-chip) demon-
strated association of MLL with the promoter regions in thou-
sands of genes (Guenther et al., 2005). This prompted the
question of whether the MLL-AF4 fusion influences a select set
of genes such as HoxA genes or whether there are more wide-
spread histone methylation abnormalities in Mll-AF4 leukemias.
We performed ChIP-chip analysis on three mouse Mll-AF4
B-pr ALLs and three normal pre-B samples using an antibody
against H3K79me2 and Affymetrix 1R mouse promoter arrays.
These studies verified an increase in H3K79me2 across the
HoxA cluster in leukemia cells (Figure 4D). A second group of
six murine Mll-AF4 ALLs confirmed H3K79me2 across the
HoxA loci but not the HoxB, HoxC, or HoxD clusters (Figures
S5A–S5C). An expanded view across the genome revealed
thousands of loci with significant H3K79me2 in both normal
pre-B cells and ALL cells, as would be expected given a normal
role for H3K79me2 in epigenetic regulation. However, on a
comparative basis, there were 1186 promoter regions in which
H3K79me2 was increased in the leukemia cells in comparison
to normal pre-B cells (B-pr ALL H3K79 signature), whereas
only 285 promoter regions had H3K79me2 that was higher in
normal pre-B cells (pre-B H3K79 signature) (Figure 4E).
As H3K79me2 has been associated with positive regulation of
transcription (Schubeler et al., 2004; Shilatifard, 2006), we used
GSEA to determine whether H3K79me2 was correlated with
gene expression. Genes associated with increased H3K79me2
in Mll-AF4-induced leukemia cells (B-pr ALL H3K79 signature)
were highly enriched for genes with elevated mRNA expression
in leukemia cells (p < 0.005; Figure 4F). Likewise, genes with
elevated H3K79me2 within normal pre-B cells (pre-B H3K79
signature) were associated with elevated expression in normal
pre-B cells (p < 0.005; Figure 4G). These analyses demonstrate
that ectopic H3K79me2 in Mll-AF4 leukemias is associated
with enhanced gene expression.
H3K79 Methylation in Human MLL-Rearranged ALLs
To assess whether similar abnormalities in H3K79me2 exist in
human MLL-rearranged ALLs, we assessed histone methylationancer Cell 14, 355–368, November 4, 2008 ª2008 Elsevier Inc. 359
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cells. First, we performed ChIP-qPCR to assess H3K79me2 as-
sociated with HOXA cluster loci. We found elevated H3K79me2
associated with multiple HOXA genes (Figure 5A). Next, we
performed ChIP-chip analyses on five MLL-rearranged ALLs
and five BM LinCD34+CD19+ cell samples using Affymetrix
1R human promoter arrays. The data demonstrate elevation of
H3K79me2 associated with multiple HOXA cluster genes similar
to that seen in the mouse leukemias (Figure 5B; Figure S6A). We
assessed genome-wide differences in H3K79me2 in MLL-rear-
ranged ALL as compared to normal CD34/CD19+ cells just as
we did for murine cells. There were many genomic regions asso-
ciated with H3K79me2 in both cell types. We found elevated
H3K79me2 associated with 1378 promoter regions in the leuke-
mias and elevated H3K79me2 associated with 562 promoter
regions in the normal samples, thus demonstrating that more
genes are associated with increased H3K79me2 in MLL-rear-
ranged leukemias as compared to normal cells (Figure 5C). Since
Figure 3. Gene Expression in Normal and Malignant Mouse B Cells and Comparison to Human Leukemias
(A) Hierarchical clustering using 10,218 filtered (minimum fold 3; minimum delta 100; background 20; ceiling 20,000) probe sets.
(B) Expression of HoxA, B, C, and D cluster genes in normal developing B lymphocytes and B-pr ALL cells.
(C) Gene set enrichment analysis (GSEA) of gene expression in humanMLL-rearranged ALL (n = 20) as compared to MLL-germline ALL (n = 40) (Ross et al., 2003)
using the top 386 genes identified as highly expressed in murine Mll-AF4 ALL as a gene set. Left: GSEA enrichment plot. Right: the top 50 genes showing in-
creased expression in human MLL-rearranged leukemias.360 Cancer Cell 14, 355–368, November 4, 2008 ª2008 Elsevier Inc.
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H3K79 Methylation in MLL-Rearranged ALLthe general trend in H3K79me2 appeared similar in mouse and
human cells, we were interested to see whether there was over-
lap between the genes associated with H3K79me2 in mouse and
human cells. We compared the B-pr ALL H3K79 signature
derived from mouse and human cells and identified 369 genes
associated with increased H3K79me2 in both mouse and human
MLL-AF4 leukemias (Figure 5D). We also identified 48 genes
associated with increased H3K79me2 in normal B-pr cells in
mouse and human (Figure 5D). These data show that the epige-
netic differences between MLL-rearranged ALL and normal B-pr
cells are similar between our mouse model and the human
disease, with more genes associated with enhanced
H3K79me2 in leukemia cells than in normal cells.
Next, we reasoned that genes found to be associated with
H3K79me2 in both mouse and human MLL-AF4 leukemias
may represent a set of MLL-AF4 genes and should be function-
ally associated with increased gene expression in human
MLL-rearranged ALLs as compared to ALLs that are not driven
by MLL fusion oncoproteins. We performed GSEA using the 369
genes found in the mouse/human H3K79me2 overlap as a gene
set and gene expression data from MLL-rearranged and germ-
line ALL samples (Ross et al., 2003). The analysis demonstrated
significant correlation between elevated H3K79me2 and ele-
vated mRNA expression in MLL-rearranged ALL in comparison
to other ALLs (p < 0.02; Figure 5E). The 48 genes that were com-
mon to mouse and human normal pre-B cells were not associ-
ated with gene expression changes in either MLL-rearranged
or other ALLs (p < 0.49; Figure 5F). These data demonstrate
that ectopic H3K79me2 is associated with gene expression in
human leukemias just as in mouse leukemias.
H3K79me2 Profiles Distinguish Human
MLL-Rearranged ALL from Other ALLs
Having demonstrated that we can identify histone methylation
abnormalities associated with the presence of MLL-AF4 in mouse
as well as human MLL-rearranged leukemias, we wondered
whether the histone methylation abnormalities were sufficiently
different between MLL-rearranged and MLL-germline leukemias
such that global patterns of H3K79me2 could be used to distin-
guishMLL-rearranged ALLs fromMLL-germline ALLs and normal
B cell progenitors. We assessed genome-wide patterns of
H3K79me2 in five MLL-rearranged ALL samples, seven MLL-
germline ALL samples, and five normal controls. Similar to normal
pre-B cells and MLL-rearranged leukemia, ALL samples with
germline MLL had thousands of loci with H3K79me2. We devel-
oped a method to use ChIP-chip histone methylation data to clus-
ter samples. After individually processing each promoter array
with an enrichment p value cutoff of 105, we associated the re-
sulting ChIP-chip regions with RefSeq genes if the site fell within
a window extending from500 to +2500 bp of the transcriptional
start site. We retained only those genes that had H3K79me2 in at
least 3 of the 17 samples. This filtering identified 5438 distinct
geneswithH3K79me2. Remarkably, the H3K79epigenetic profile
of MLL-rearranged leukemia samples was clearly distinct from
normal CD34/CD19+ cells and from MLL-germline ALLs when
clustered with hierarchical clustering (Figure 6A) or when pro-
jected using principal component analysis (PCA) (Figure 6B).
Thus, MLL-rearranged ALLs have a global H3K79me2 profile
that is sufficiently distinct to distinguish MLL-rearranged ALLsCfrom other lymphoblastic leukemias, just as profiles of mRNA ex-
pression can distinguish these classes (Armstrong et al., 2002).
Next, we identified the genes that had the highest mean histone
methylation score in MLL-rearranged samples compared to
normal CD34/CD19+ cells andMLL-germline ALL cells. This anal-
ysis identified a number of genes previously associated withMLL-
rearranged leukemias, including HOXA genes, MEIS1, RUNX2,
PROM1, and FLT3 (Figures 6C and 6D; Figure S6B) (Armstrong
et al., 2002, 2003; Krivtsov and Armstrong, 2007; Krivtsov et al.,
2006; Rozovskaia et al., 2001). A number of other genes of inter-
est, includingBCL2 andCEBPa, have previously been implicated
in leukemias, but not specifically those withMLL rearrangements.
CEBPa is of particular interest given its role in specification of
myeloid cell fate and the propensity for myeloid gene expression
in MLL-AF4 ALLs. These data demonstrate a unique H3K79me2
profile for MLL-rearranged leukemias as compared to other
ALLs, which includes a number of loci previously identified as
playing important roles in MLL-rearranged leukemias.
DOT1L Suppression Inhibits H3K79me2 and HOXA
Expression in MLL-AF4 Cells
We have demonstrated a strong correlation between H3K79me2
and aberrant HOXA gene expression in MLL-AF4 cells. Thus, we
were interested to know whether continued expression of the
H3K79 methyltransferase DOT1L was required to maintain aber-
rant HOX gene expression, as a first step toward assessing
DOT1L as a potential therapeutic target in this disease. We de-
veloped two lentiviral-based shRNA constructs directed toward
DOT1L and transduced two different t(4;11) (MLL-AF4) cell lines.
Forty-eight hours after transduction with a viral titer sufficient to
transduce >90% of the cells, DOT1L expression was assessed
by quantitative RT-PCR, which demonstrated suppression of
DOT1L RNA to approximately 20%–30% of control levels
(Figures 7A and 7B). Suppression of DOT1L protein expression
was confirmed in one of the two cell lines (Figure 7B). Seventy-
two hours after transduction, we assessed H3K79me2 across
the HOXA cluster and found diminished H3K79me2 in cells
transduced with the DOT1L-directed shRNA (Figures 7C and
7D). This reduction of H3K79 across the HOXA locus resulted
in decreased expression of both HOXA5 and HOXA9 (Figures
7E and 7F). These data demonstrate that continued expression
of DOT1L is required for H3K79me2 and HOXA gene expression
in MLL-AF4 cells.
DISCUSSION
Translocations involving the MLL gene result in both AML and
ALL in humans. MLL-AF9 and MLL-AF4 are the most common
translocations resulting in AML and ALL, respectively. Although
a number of retroviral and genetically engineered mouse models
of MLL fusion-mediated AML have been developed, models
recapitulating MLL-AF4-mediated ALL have been more elusive.
Ectopic expression of MLL-AF4 through retroviral transduction
has been difficult, and other genetically engineered mouse
models have resulted in myelodysplasia or mature B cell lympho-
mas. We report here the generation of a conditional knockin
model in which the MLL-AF4 fusion product is expressed within
the context of the endogenous MLL locus. Upon conditional
activation, mice develop AML or ALL, the latter with anancer Cell 14, 355–368, November 4, 2008 ª2008 Elsevier Inc. 361
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H3K79 Methylation in MLL-Rearranged ALLFigure 4. ChIP Analysis of Histone Methylation in Mouse Mll-AF4 B Precursor ALL and Normal Pre-B Cells
(A) Fold increase in trimethyl H3K4, trimethyl H3K27, trimethyl H3K36, and dimethyl H3K79 marks associated with the Hoxa9 promoter in B-pr ALL cells over
pre-B cells as assayed by ChIP-qPCR. H3K4 p = 0.05, H3K79 p = 0.005; two-tailed t test. Error bars represent ±SD between four independent experiments.
(B) Correlation of HoxA9 expression with H3K79me2 content on the HoxA9 promoter. HoxA9/Gapdh ratio (HoxA9 expression) was assessed by RT-qPCR, and
H3K79me2 content (percent of input) on the HoxA9 promoter was assessed by ChIP-qPCR in pre-B (C, n = 2) and B-pr ALL (B, n = 9) samples. Pearson
correlation R = 0.911; p < 0.0001 by two-tailed t test.
(C) Enrichment of H3K79me2 associated with HoxA cluster promoter regions in B-pr ALL and normal pre-B cells expressed as a percentage of input. Error bars
represent ±SD of triplicates in one of three independent experiments.
(D) Identically scaled average tracks from ChIP-chip analysis representing HoxA cluster loci in normal pre-B (n = 3) and B-pr ALL (n = 3) cells.
(E) Graphical (bar) representation of regions associated with H3K79me2 in normal pre-B and B-pr ALL cells. Averaged model-based analysis of tiling (MAT) scores
from genome-wide promoter analysis of three pre-B cell and three B-pr ALL samples were used to define genomic regions possessing significant H3K79 signal
(p < 105) over background. The bars represent 285 genes that were identified to be associated with H3K79me2 in pre-B cells but not in B-pr ALL and 1186 genes
associated with H3K79me2 in B-pr ALL but not in pre-B cells.
(F) Correlation of H3K79me2 marks with gene expression in B-pr ALL. GSEA was performed using the top 300 genes by MAT score (out of 1186 genes) in the B-pr
ALL H3K79 signature as a gene set. This gene set was assessed for enrichment in the genes more highly expressed in B-pr ALL as compared to normal mouse362 Cancer Cell 14, 355–368, November 4, 2008 ª2008 Elsevier Inc.
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acute B precursor cell leukemia. The gene expression signature
of murine Mll-AF4 ALL cells was found to be highly enriched in
the gene expression profile of human ALL samples with MLL
rearrangements as compared to ALL samples with germline
MLL. Therefore, this murine model recapitulates human MLL-
AF4-mediated ALL in terms of both disease phenotype and over-
all patterns of gene expression. We note that our mice have a
propensity toward AML development, which differs from the
strong association between t(4;11) and ALL in humans. Future
studies will determine whether this is due to expression of
Mll-AF4 in different cells of origin or to microenvironmental influ-
ences as recently shown for MLL-AF9 (Wei et al., 2008). Also, the
genetic background may influence the leukemia incidence and
phenotype. The development of a faithful model of MLL-AF4
ALL will allow detailed characterization of the mechanisms of
MLL-AF4-mediated leukemogenesis, including the mechanisms
of transformation, the cell (or cells) of origin, the phenotypes of
cancer stem cells in leukemias expressing various lineage
markers, and the mechanisms associated with the development
of mixed myeloid/lymphoid (mixed-lineage) disease. Also, a faith-
ful model of MLL-AF4 ALL will allow for assessment of putative
therapeutics in a well-defined model system.
Recent studies have identified association of multiple MLL
fusion partners including AF4, AF9, and AF10 with DOT1L, a his-
tone H3K79 methyltransferase (Bitoun et al., 2007; Mueller et al.,
2007; Okada et al., 2005; Zeisig et al., 2005; Zhang et al., 2006).
We used our murine model to ask whether abnormalities in
H3K79me2 were present in Mll-AF4-mediated ALL. Genome-
wide assessment revealed enhanced H3K79me2 in comparison
to matched normal cells at many loci across the genome, includ-
ing across the HOXA cluster. This prompted a similar analysis in
human ALL samples, where we confirmed widespread abnor-
malities in H3K79me2 as a characteristic distinguishing MLL-
rearranged from MLL-germline ALLs. These results demonstrate
that in both murine and human disease mediated by MLL rear-
rangement, there are widespread changes in H3K79me2, includ-
ing on genes that are critical for leukemogenesis such asHOXA9
and MEIS1. Future studies will determine which subset of these
genes are direct MLL-AF4 target genes. The results described
here further underscore the utility of this murine model system
for providing mechanistic insight into human disease.
In both human and murine ALL, we found that ectopic
H3K79me2 was highly associated with increased mRNA expres-
sion. Wild-type MLL possesses H3K4 methyltransferase activity,
a modification associated with transcriptional ‘‘priming’’ of the
promoters of genes important for appropriate developmental
cell fate decisions (Guenther et al., 2007). Since the methyltrans-
ferase domain of MLL is invariably lost in MLL fusion proteins,
including MLL-AF4, the question arises as to how MLL fusions
promote enhanced expression of its target genes such as
HOXA genes. We found that H3K4me3 is still associated with
HOX genes in our murine MLL-AF4 model, and preliminary ex-Cperiments suggest this to also be the case in human ALL with
MLL fusions (A.V.K., unpublished data). In both human disease
and our murine model, the second MLL allele remains germline,
and thus wild-type MLL protein, or perhaps other H3K4 methyl-
transferases, may continue to regulate H3K4me3 at these loci.
However, H3K4me3 is insufficient to fully activate transcription,
which appears to require the presence of other histone modifica-
tions such as H3K79me2 for transcriptional elongation to pro-
ceed (Guenther et al., 2007). This leads to a model wherein
MLL-AF4 recruits DOT1L to MLL target genes and promotes
methylation of H3K79 at loci with existing H3K4 methylation
(i.e., by wild-type MLL or other H3K4 methyltransferases), thus
stimulating transcriptional elongation of genes that are normally
primed but not fully transcribed.
Prior studies have established that various cancer subtypes
can be distinguished on the basis of specific oncoproteins or
global mRNA expression patterns. In this study, we have demon-
strated that widespread differences in an epigenetic histone
modification can likewise distinguish different cancer subtypes,
and malignant versus normal cells. The ability to distinguish can-
cer subtypes on the basis of epigenetic profiles does not neces-
sarily offer any advantages over mRNA profiling in terms of
disease diagnosis. However, the tight linkage between oncopro-
tein (MLL-AF4), specific epigenetic changes (H3K79me2), and
altered gene expression has important therapeutic implications.
Specifically, many oncoproteins are DNA-binding proteins and
are generally not readily amenable to targeting by small mole-
cules or biologics. Pharmacologic inhibition of transcription fac-
tor function, including disrupting protein-protein or protein-DNA
interactions, remains a largely experimental undertaking with
few examples of success. A common strategy to bypass this
impasse has been to look for downstream transcriptional targets
that may be more druggable (e.g., enzymes and/or receptors).
Since oncoproteins may alter the expression of hundreds or
thousands of genes, in most cases inhibiting the activity of a
single druggable downstream target may not fully reverse the
malignant phenotype. Inhibition of epigenetic-modifying en-
zymes offers an alternative approach that is facilitated by the
fact that enzymes are generally more amenable to drug develop-
ment. Targeting the epigenetic link between an oncoprotein and
downstream gene expression changes may more broadly im-
pact the multitude of gene expression changes that in aggregate
contribute to the malignant phenotype. In the case of diseases
driven by MLL fusion proteins, development of a DOT1L inhibitor
may impact expression of a diversity of critical genes including
HOXA9, MEIS1, FLT3, and BCL2. Indeed, our data demonstrate
that suppression of DOT1L expression leads to decreased ex-
pression of HOXA cluster genes. Furthermore, a DOT1L inhibitor
might be applicable to other diseases characterized by ectopic
H3K79me2. In this regard, the ability to identify disease subtypes
that have widespread ectopic H3K79me2 would have important
implications for patient selection and stratification in testing
a DOT1L inhibitor. Inasmuch as epigenetic modifications arepre-B cells. Left: GSEA enrichment plot. Right: expression of genes corresponding to the top 50 differentially expressed genes from the B-pr ALL H3K79 signa-
ture. Normalized enrichment score (NES) = 1.88; p < 0.005.
(G) Correlation of H3K79me2 marks with gene expression in pre-B cells. GSEA was performed using 285 genes in the pre-B H3K79 signature as a gene set.
Left: GSEA enrichment plot. Right: expression of genes corresponding to the top 50 differentially expressed genes from the B-pr ALL H3K79 signature. NES =
1.91; p < 0.005.ancer Cell 14, 355–368, November 4, 2008 ª2008 Elsevier Inc. 363
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H3K79 Methylation in MLL-Rearranged ALLlikely to be linked to the maintenance of gene expression in many
human malignancies, these strategies may be applicable to
a wide variety of cancer subtypes.
EXPERIMENTAL PROCEDURES
Human Samples
Normal bone marrow samples as well as diagnostic leukemia samples (periph-
eral blood or bone marrow) were obtained with informed consent from individ-
uals treated according to protocols approved by the Institutional Review
Board at the Dana-Farber Cancer Institute between 2000 and 2007. For de-
tails, see Supplemental Experimental Procedures.
Generation of ConditionalMll-AF4 Knockin Mice
Animals were maintained at the Animal Research Facility at Children’s Hospital
Boston. Animal experiments were approved by the Institutional Animal Care
and Use Committee. The Mll-AF4stop targeting vector was assembled in the
plasmid vector Litmus 28 (New England Biolabs). We removed Cbp cDNA
from a previously described (Wang et al., 2005)Mll-Cbpstop targeting construct
using BamHI digestion and ligated in a portion of AF4 (aa 347–1210; GenBank
accession number L13773) using 50 BamHI and 30 blunt ends. For further de-
tails, see Supplemental Experimental Procedures. Mx1-Cre3MA4 mice were
generated by crossing Mll-AF4stop (MA4) males with females transgenic for
Mx1-Cre. Mx1-Cre 3 MA4 mice (6–8 weeks old) and control littermates were
injected intraperitoneally with 400 mg of polyinosinic/polycytidylic acid (pIpC;
Sigma-Aldrich) three times over a 6 day interval.
Bone Marrow Reconstitution Assay and Retroviral Infections
Bone marrow was collected from tibias and femurs of MA4 mice treated with or
without 5-FU (Sigma-Aldrich). Red blood cells were lysed using RBC lysis
buffer (Puregene), and the remaining cells were washed twice in PBS (Invitro-
gen) and transduced with ‘‘hit-and-run’’ Cre (Silver and Livingston, 2001)
retrovirus (produced as described previously in Krivtsov et al., 2006) overnight
in IMDM supplemented with 10% FBS (Invitrogen); 1/100 penicillin/streptomy-
cin (Invitrogen); 10 ng/ml each of IL-3, IL-6, and IL-7; 50 ng/ml each SCF and
FLT3 (PeproTech); and 7 mg/ml polybrene (Sigma-Aldrich). Syngeneic recipient
mice were lethally irradiated (23 700 rads) or sublethally irradiated (600 rads).
Retrovirally transduced cells were transplanted retro-orbitally. Detection of
Mll-AF4 is described in Supplemental Experimental Procedures.
Flow Cytometry
Labeling of cells for fluorescence-activated cell sorting (FACS) was performed
on ice in PBS supplemented with 0.5% horse serum (Invitrogen) using conju-
gated antibodies purchased from BD PharMingen, eBioscience, or Invitrogen
unless otherwise indicated. Details of the antibodies used can be found in
Supplemental Experimental Procedures.
Transduction with shRNA Constructs
shRNAs cloned into hairpin pLKO.1 lentiviral vector were synthesized by the
Harvard/MIT Broad Institute RNA consortium utilizing a complex selection al-Cgorithm to minimize off-target effects (http://www.broad.mit.edu/rnai/trc/).
The target sequences for suppression of human DOT1L (NM_032482) were
DOT1L shRNA1, 50-CGCCAACACGAGTGTTATATT-30; DOT1L shRNA2, 50-C
CGCAAGAAGAAGCTAAACAA-30; and nontargeting GFP control shRNA, 50-G
CAAGCTGACCCTGAAGTTCA-30. Details of lentiviral transduction can be
found in Supplemental Experimental Procedures.
RNA Amplification and Microarray Data Analysis
1–5 3 105 cells of different populations were used to isolate RNA. Twenty
nanograms of total RNA was amplified and labeled using Ovation RNA Ampli-
fication System V2 (NuGEN). Expression data were analyzed with GenePattern
release 3.1 and the GSEA 2.0 software package (http://www.broad.mit.edu/
tools/software.html). Details of the gene expression analysis can be found in
Supplemental Experimental Procedures.
Chromatin Immunoprecipitation, DNA Amplification, Data Analysis,
and PCR Analysis
3–10 3 105 FACS-sorted cells were fixed in 1% formaldehyde with gentle ro-
tation for 10 min, and the reaction was stopped by addition of glycine (125 mM
final concentration). The fixed cells were washed twice with PBS, resuspended
in SDS buffer, and further processed as described previously (Bracken et al.,
2006) using anti-dimethyl H3K79 (Abcam 3594), anti-trimethyl H3K4 (Upstate
05-745), anti-trimethyl H3K36 (Abcam 9050), or anti-trimethyl H3K27 (Upstate
07-449). Eluted DNA fragments were used directly for qPCR with HoxA pro-
moter-specific primers (Bracken et al., 2006) and Sybr GreenER qPCR mix
using an ABI 7700 Sequence Detection System. Alternatively, ChIP DNA frag-
ments were amplified using ligation-mediated PCR as described elsewhere
(http://chiponchip.org/protocol_itm3.html) (experiment 1 in Figure 4) or using
a WGA1 GenomePlex Whole Genome Amplification kit (Sigma) (experiment
2 in Figure S5) and subjected to hybridization with Affymetrix 1R mouse or
1R human promoter arrays.
Identification of ChIP-Chip Regions
M.E.L. directed computational analyses. The model-based analysis of tiling
(MAT) array algorithm (Johnson et al., 2006) was used to identify genomic re-
gions (‘‘hits’’) and highest mean histone methylation scores (MAT scores) as-
sociated with those regions on Affymetrix promoter tiling arrays enriched by
ChIP. MAT was run with the following parameters to capture regions of in-
creased signal intensity: bandwidth = 300, maximum gap = 300, minimum
probes = 10, window p value cutoff = 13 105. The resulting hits were all false
discovery rate (FDR) < 5, so no additional filtering was used. The MAT library
and mapping files were based on the March 2006 Human Genome Assembly
(HG18) or the February 2006 Mouse Genome Assembly (MM8) as appropriate.
Hits flagged by MAT as mapping to repeat regions were excluded from consid-
eration in all cases.
Linking ChIP Hits to RefSeq Genes
The University of California, Santa Cruz RefGene tables (ftp://hgdownload.
cse.ucsc.edu/goldenPath) for the human and mouse genomes (HG18 and
MM8, respectively), which contain transcription start site (TSS) and endFigure 5. ChIP-Chip Analysis of Histone Methylation in Human MLL-Rearranged ALL and Normal Pre-B Cells
(A) Enrichment of H3K79 dimethylation marks associated with HOXA cluster promoters in t(4;11) ALL and human LinCD34+CD19+ (CD34/19+) BM cells ex-
pressed as percentage of input as assessed by ChIP-qPCR. Error bars represent ±SD of triplicates in one of three independent experiments.
(B) Identically scaled average tracks from ChIP-chip analysis of H3K79me2 modifications associated with HOXA cluster loci in human CD34/19+ cells (n = 5) or
MLL-rearranged ALL (MLL-r ALL) (n = 5).
(C) Graphical (bar) representation of regions associated with H3K79me2 in normal CD34/CD19+ and MLL-rearranged ALL cells. 562 genes were identified in
CD34/19+ cells but not in MLL-rearranged ALL (CD34/19+: high), whereas 1378 genes with significant H3K79 signal were present in MLL-rearranged ALL but
not CD34/19+ cells (MLL-r ALL: high).
(D) Forty-eight genes had higher H3K79 ChIP-chip signals in both mouse pre-B and human CD34/19+ cells as compared to mouse and human leukemias. 369 genes
had higher H3K79 ChIP-chip signals in both mouse Mll-AF4 and human MLL-rearranged ALL as compared to normal B cells. p < 0.0001 by Fisher’s exact test.
(E) GSEA analysis of the 369-gene signature with elevated H3K79me2 found in both human MLL-rearranged ALL and mouse B-pr ALL demonstrated enrichment
of the gene expression signature inMLL-rearranged ALL as compared toMLL-germline ALL (NES = 1.63, p < 0.019). Left: GSEA enrichment plot. Right: heat map
of expression for the top 50 probe sets in MLL-rearranged ALL as compared to MLL-germline ALL (Ross et al., 2003).
(F) GSEA analysis of the 48 genes with elevated H3K79me2 found in both human CD34/CD19+ BM and mouse pre-B cells found no enrichment of the signature
in MLL-rearranged ALL as compared to MLL-germline ALL (NES = 0.97, p > 0.49). Left: GSEA enrichment plot. Right: heat map of expression for 36 probe sets in
MLL-rearranged ALL as compared to MLL-germline ALL (Ross et al., 2003).ancer Cell 14, 355–368, November 4, 2008 ª2008 Elsevier Inc. 365
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table (downloaded May 24, 2007) from the National Center for Biotechnol-
ogy Information (NCBI) (ftp://ftp.ncbi.nih.gov/gene/DATA/) via reference
RNA accession number. Chromosomal positions were then used to associ-
ate ChIP hits with RefSeq gene IDs. Specifically, hits falling within a window
of 0.5 kb to +2.5 kb of a given RefSeq TSS were annotated as being
associated with that gene. This window is more restrictive on the 50 side
than the regions tiled on the promoter arrays (7.5 kb–10 kb 50 to 2.5 kb
30 of TSS).
Linking Human and Mouse Genes
Homologous human and mouse genes were linked via the NCBI HomoloGene
database. Mouse and human gene symbols and IDs were extracted from each
homology group that included both human and mouse homologs.
Clustering and Principal Component Analysis of ChIP hits
Individual samples were processed using MAT as above, and the resulting
ChIP hits were linked to RefSeq genes as before. A list of represented genes,
G, was generated from the nonredundant union of all genes associated with
Figure 6. Unsupervised and Supervised Analysis of ChIP-Chip Data for H3K79 Methylation inMLL-Rearranged ALL,MLL-Germline ALL, and
CD34/19+ Cells
(A) Hierarchical clustering of 5438 genes associated with H3K79me2 demonstrates that MLL-rearranged ALL samples cluster together and are separate from
other MLL-germline ALLs and normal B-pr cells.
(B) Principal component analysis (PCA) of the same 5438 genes associated with H3K79me2 separatesMLL-rearranged ALL (red) from MLL-germline ALL (black)
and CD34/19+ cells (green).
(C) The top 50 genes associated with H3K79me2 in MLL-rearranged ALL compared to the rest of the samples. Genes were ranked based on difference of mean
MAT scores between MLL-rearranged (MLL-r) ALL samples and MLL-germline (MLL-g) ALL plus CD34/19+ cells.
(D) Expression of genes identified in Figure 6C. Of the 50 genes, 37 had corresponding probe sets on U133A arrays.366 Cancer Cell 14, 355–368, November 4, 2008 ª2008 Elsevier Inc.
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H3K79 Methylation in MLL-Rearranged ALLa ChIP hit in any sample. A matrix, M, was constructed such that for each gene
i in G and for each sample j, Mi,j = 0 if the j
th sample had no ChIP hit associated
with gene i or Mi,j = MAT score of the ChIP hit in sample j associated with gene i.
Hierarchical clustering by sample of the resulting matrix was performed using
the clustering tool of GenePattern 2.0. Principal component analysis (PCA)
was performed using an R script (http://www.r-project.org/) based on the
PCA Methods library from the Bioconductor project (http://bioconductor.
org). PCA images were generated using Origin 7.5.
ACCESSION NUMBERS
Microarray data reported herein have been deposited at the NCBI Gene Ex-
pression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) with the accession
number GSE12363.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, Sup-
plemental References, and six figures and can be found with this article online
at http://www.cancercell.org/supplemental/S1535-6108(08)00328-0.
Figure 7. shRNA-Mediated DOT1L Suppression in Human MLL-AF4
Cell Lines
(A and B) SEMK2 (A) or RS4;11 (B) ALL cell lines possessing a t(4;11) were
transduced with either a control shRNA or one of two different shRNAs that tar-
get DOT1L, and DOT1L RNA expression was assessed by quantitative RT-
PCR and western blot for RS4;11 cells 72 hr after transduction (inset). Error
bars represent ±SD of duplicates in one of two independent experiments.
(C and D) Assessment of H3K79me2 associated with HOXA cluster genes us-
ing ChIP 96 hr after treatment of SEMK2 (C) or RS4;11 (D) cells with either
a control or DOT1L-directed shRNA (DOT1Lsh1). Error bars represent ±SD
of duplicates in one of two independent experiments.
(E and F) Assessment of HOXA5 and HOXA9 expression in SEMK2 (E) or
RS4;11 (F) cells 96 hr after lentiviral transduction with either control or one of
two different shRNA constructs. Error bars represent ±SD of duplicates in
one of two independent experiments.CACKNOWLEDGMENTS
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